Overcoming Endocrine Resistance in Breast Cancer

Research output: Contribution to journalReview articlepeer-review

238 Scopus citations


Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype. Treatment of ER+ breast cancer comprises interventions that suppress estrogen production and/or target the ER directly (overall labeled as endocrine therapy). While endocrine therapy has considerably reduced recurrence and mortality from breast cancer, de novo and acquired resistance to this treatment remains a major challenge. An increasing number of mechanisms of endocrine resistance have been reported, including somatic alterations, epigenetic changes, and changes in the tumor microenvironment. Here, we review recent advances in delineating mechanisms of resistance to endocrine therapies and potential strategies to overcome such resistance.

Original languageEnglish (US)
Pages (from-to)496-513
Number of pages18
JournalCancer Cell
Issue number4
StatePublished - Apr 13 2020


  • ESR1
  • SERD
  • SERM
  • aromatase inhibitor
  • breast cancer
  • endocrine resistance
  • estrogen receptor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Overcoming Endocrine Resistance in Breast Cancer'. Together they form a unique fingerprint.

Cite this